Sanofi launches trial of revolutionary flu vaccine
Sanofi-Aventis has launched a mid-stage study of a new seasonal flu vaccine that hopes to advance a completely new method to make vaccines. The vaccine is made from cell cultures as opposed to the traditional egg-based approach. This experimental vaccine uses a cell line--PER.C6--licensed from Crucell. Sanofi-Aventis' closely-watched development program is expected to short circuit the slow, crude manufacturing process now in place and help revolutionize the whole vaccine business.
"This project is part of a contract awarded in 2005 by the U.S. Department of Health and Human Services (HHS) aimed at accelerating the development of a new cell culture-based influenza vaccine," Sanofi-Aventis said in a statement.
- take a look at the release from Sanofi
- read the report from In-PharmaTechnologist.com
Related Articles:
Sanofi vaccine effective against new bird flu strains. Report
Sanofi's avian flu drug gets mixed results. Report
Sanofi underscores pipeline advances, setbacks. Report
What's Warren Buffett buying now? Report
Be the first to comment
More stories about Crucell new bird Department of Health and Human Services flu vaccine flu Avian Flu Vaccines pipeline Sanofi Aventis
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets